BioWorld

Feb. 24, 2010

Cayston Nod a Small Win for Gilead Ahead of New HIV Data

Gilead Sciences Inc.'s ongoing strategy to diversify its pipeline scored a small victory with the approval of inhaled aztreonam lysine drug Cayston, but there's no question the firm's future growth still hinges largely on its next-generation HIV pipeline. (BioWorld Today) Read More

Ception's Phase II Asthma Data Prompt $250M Cephalon Buyout

FDA Panel Gives Solid Backing for Salix Cirrhosis Medication

PharmAthene Gets $78.4M More in Anthrax Pact Modification

Invirase Data Spark Warning: Possible PI Combo Heart Risk

Biomarker-based Drug Making not Fast, but Can Be Efficient

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...